127.80
-8.20 (-6.03%)
| Penutupan Terdahulu | 136.00 |
| Buka | 140.00 |
| Jumlah Dagangan | 537,861 |
| Purata Dagangan (3B) | 80,150 |
| Modal Pasaran | 4,459,068,928 |
| Harga / Buku (P/B) | 20.53 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| EPS Cair (TTM) | -1.36 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.37% |
| Nisbah Semasa (MRQ) | 25.98 |
| Aliran Tunai Operasi (OCF TTM) | -29.23 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.42 M |
| Pulangan Atas Aset (ROA TTM) | -22.23% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.43% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Belite Bio, Inc | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.25 |
|
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 53.93% |
| % Dimiliki oleh Institusi | 0.75% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 194.00 (Mizuho, 51.80%) | Beli |
| Median | 169.50 (32.63%) | |
| Rendah | 132.00 (Benchmark, 3.29%) | Beli |
| Purata | 166.25 (30.09%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 136.69 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Mizuho | 02 Dec 2025 | 194.00 (51.80%) | Beli | 150.84 |
| 20 Nov 2025 | 105.00 (-17.84%) | Pegang | 109.18 | |
| HC Wainwright & Co. | 01 Dec 2025 | 185.00 (44.76%) | Beli | 154.02 |
| 15 Sep 2025 | 98.00 (-23.32%) | Beli | 66.80 | |
| Cantor Fitzgerald | 24 Nov 2025 | 154.00 (20.50%) | Beli | 136.00 |
| Benchmark | 31 Oct 2025 | 132.00 (3.29%) | Beli | 105.91 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |